Hydroxychloroquine pre-exposure prophylaxis for COVID-19 among healthcare workers: Initial experience from India
Dr Manish Soneja, Harshith B Kadnur, Anivita Aggarwal, Komal Singh, Ankit Mittal, Neeraj Nischal, Praveen Tirlangi, Adilrashid Khan, Devashish Desai, Ankesh Gupta, Arvind Kumar, Pankaj Jorwal, Ashutosh Biswas, Ravindramohan Pandey, Naveet Wig, Randeep Guleria
Journal of Family Medicine and Primary Care, doi:10.4103/jfmpc.jfmpc_1177_21
Background: Hydroxychloroquine (HCQ) had generated considerable interest for coronavirus disease 2019 (COVID-19) prophylaxis. We conducted a prospective observational study at a tertiary care hospital in India, with dedicated COVID-19 care facilities. Objectives: Primary objective was incidence of adverse effects, secondary objective being efficacy in preventing COVID-19. Methods: Healthcare workers were recruited and grouped based on voluntary HCQ prophylaxis as per national guidelines. Side effects in HCQ group were graded in accordance with national cancer institute-common terminology criteria for adverse events (NCI-CTCAE) version 5.0. At 3-7-week follow-up, groups were compared for COVID-19 exposure, symptoms development and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR results. Results: Among 358 participants recruited, 216 (60.3%) were males and mean age was 31.2 ± 6.6 years. Chemoprophylaxis was initiated by 258 (72%) participants. After loading dose, 7 (2.7%) reported grade 2 and 1 (0.4%) grade 3 adverse effects. Discontinuation of HCQ due to side effects was reported in 11 (4.3%) participants. Electrocardiogram was done by 50 (19.4%) participants on HCQ; no abnormalities were noted. A total of 106 (41%) among those taking and 63 (63%) among those not taking HCQ were tested for SARS-CoV-2 due to influenza-like illness or significant exposure. Among all participants, 25 (6.9%, 95% confidence interval [CI] 4.3-9.6) developed COVID-19 during the study period. In the group taking HCQ, 10 (3.9%) tested positive compared to 15 (15%) in the group not taking HCQ (P < 0.001). Odds ratio with HCQ intake was 0.34 (95% CI 0.13-0.83, P = 0.01) and the number needed to treat was 12. Conclusion: HCQ is safe at the recommended dose for pre-exposure prophylaxis of COVID-19.
Conflicts of interest There are no conflicts of interest.
References
Abella, Jolkovsky, Biney, Uspal, Hyman et al., Prevention and treatment of COVID-19 with hydroxychloroquine (PATCH) investigators. Efficacy and safety of hydroxychloroquine vs placebo for preexposure SARS-CoV-2 prophylaxis among health care workers: A randomized clinical trial, JAMA Intern Med
Al-Kofahi, Jacobson, Boulware, Matas, Kandaswamy et al., Finding the dose for hydroxychloroquine prophylaxis for COVID-19: The desperate search for effectiveness, Clin Pharmacol Ther
B E N -Z V I I , K I V I T Y S , L A N G E V I T Z P , S H O E N F E L D, Hydroxychloroquine: From malaria to autoimmunity, Clin Rev Allergy Immunol
Barnabas, Brown, Bershteyn, Karita, Johnston et al., Hydroxychloroquine as postexposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 infection. A randomized trial, Ann Intern Med
Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., A Randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19, N Engl J Med
Fantini, Scala, Chahinian, Yahi, Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection, Int J Antimicrob Agents
Guan, Ni, Hu, Liang, Ou et al., Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med
Keeley, Evans, Colton, Ankcorn, Cope et al., Roll-out of SARS-CoV-2 testing for healthcare workers at a large NHS Foundation Trust in the United Kingdom, March 2020, Euro Surveill
Kono, Tatsumi, Imai, Saito, Kuriyama et al., Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: Involvement of p38 MAPK and ERK, Antiviral Res
Kucirka, Lauer, Laeyendecker, Boon, Lessler, Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure, Ann Intern Med
Lancet, COVID-19: Protecting health-care workers, Lancet
Lee, Son, Peck, Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?, Int J Antimicrob Agents
Liu, Cao, Xu, Wang, Zhang et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov
Mercuro, Yen, Shim, Maher, Mccoy et al., Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19), JAMA Cardiol
Rajasingham, Bangdiwala, Nicol, Skipper, Pastick et al., Hydroxychloroquine as pre-exposure prophylaxis for coronavirus disease 2019 (COVID-19) in healthcare workers: A randomized trial, Clin Infect Dis
Rathi, Ish, Kalantri, Kalantri, Hydroxychloroquine prophylaxis for COVID-19 contacts in India, Lancet Infect Dis
Remuzzi, Remuzzi, COVID-19 and Italy: What next?, Lancet
Revollo, Tebe, Peñafiel, Blanco, Perez-Alvarez et al., Hydroxychloroquine pre-exposure prophylaxis for COVID-19 in healthcare workers, J Antimicrob Chemother
Tilangi, Desai, Khan, Soneja, Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: A prudent approach, Lancet Infect Dis
Wallace, Tse, Hanrahan, Davies, Petri, Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: Survey results from 3127 patients with SLE conducted by the Lupus Foundation of America, Lupus Sci Med
Wang, Fortin, Li, Panaritis, Gans et al., Discontinuation of antimalarial drugs in systemic lupus erythematosus, J Rheumatol
Wang, Yang, Liu, Gua, Zhang et al., SARS coronavirus entry into host cells through a novel clathrin-and caveolae-independent endocytic pathway, Cell Res
Yao, Ye, Zhang, Cui, Huang et al., In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis
